Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Daito Pharmaceutical Co.,Ltd. (4577.T)
JPY1,313.00
-16.00 (-1.20%)
JP JPX Healthcare Drug Manufacturers - Specialty & Generic
Address
326, Yokamachi 939-8567
Toyama, JP
Toyama, JP
CEO
Hiroshi Matsumori
Website
daitonet.co.jp
IPO
2010-03-24
ISIN JP3486150000
Description
Daito Pharmaceutical Co.,Ltd. is a global entity primarily involved in the creation and sale of a diverse range of pharmaceutical products. Their offerings span active pharmaceutical ingredients (APIs) and chemical intermediates, alongside both prescription and over-the-counter (OTC) medications, and home-delivered medicines. These products are available in various formats, including tablets, capsules, lozenges, granules, and powdered forms. Beyond its own brand, the company also provides contract manufacturing services, developing medicinal formulations for other pharmaceutical firms. Additionally, Daito Pharmaceutical markets health food products. Established in 1942, it was initially known as Daito Corporation, changing to its current name in 1992, and maintains its headquarters in Toyama, Japan.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
JPY1,313.00
-16.00 (-1.20%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
85.8K
Beta
0.19
Float Shares
26.25M
Free Float %
90.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.42% | -2.20% | -4.68% | -18.23% | -8.38% | -11.62% | +22.03% | +12.38% | -19.38% | -4.19% | +93.92% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
1,313.00
DCF (Unlevered)
113.99
-91.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.84
Grey zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
5 / 10
Developing
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+0.0% Q2'26: -0.8% (vs Q2'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+71.3% ★ Q2'26: +35.3% (vs Q2'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+10.0% ★ Q2'26: +0.0% (vs Q2'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+7.2% Q2'26: +6.4% (vs Q2'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+4.6% Q2'26: +5.8% (vs Q2'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-3.3% ★ Q2'26: -4.4% (vs Q2'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.16× Q2'26: 1.16× (vs Q2'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
May 2016 actual |
May 2017 actual |
May 2018 actual |
May 2019 actual |
May 2020 actual |
May 2021 actual |
May 2022 actual |
May 2023 actual |
May 2024 actual |
May 2025 actual |
May 2026 1 Rev. Ana. 1 EPS Ana. |
May 2027 1 Rev. Ana. 1 EPS Ana. |
May 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
36.33B
est: 37.40B (-2.9%)
|
37.97B
est: 40.50B (-6.2%)
|
39.88B
est: 40.00B (-0.3%)
|
41.14B
est: 41.30B (-0.4%)
|
45.00B
est: 45.20B (-0.4%)
|
48.71B
est: 49.00B (-0.6%)
|
43.46B
est: 43.00B (+1.1%)
|
45.10B
est: 45.50B (-0.9%)
|
46.90B
est: 47.40B (-1.1%)
|
50.64B
est: 49.00B (+3.4%)
|
51.00B
51.00B – 51.00B
+4.1% YoY
|
54.50B
54.50B – 54.50B
+6.9% YoY
|
58.00B
58.00B – 58.00B
+6.4% YoY
|
| EBITDA |
6.20B
est: 6.93B (-10.6%)
|
6.70B
est: 7.51B (-10.8%)
|
7.02B
est: 7.41B (-5.3%)
|
7.40B
est: 7.65B (-3.3%)
|
8.31B
est: 8.38B (-0.8%)
|
9.07B
est: 9.08B (-0.1%)
|
10.04B
est: 7.97B (+26.0%)
|
8.96B
est: 8.43B (+6.2%)
|
7.92B
est: 8.56B (-7.5%)
|
7.41B
est: 8.85B (-16.3%)
|
9.21B
9.21B – 9.21B
+4.1% YoY
|
9.85B
9.85B – 9.85B
+6.9% YoY
|
10.48B
10.48B – 10.48B
+6.4% YoY
|
| EBIT |
3.56B
est: 4.01B (-11.4%)
|
3.88B
est: 4.34B (-10.7%)
|
4.17B
est: 4.29B (-2.8%)
|
4.55B
est: 4.43B (+2.7%)
|
5.36B
est: 4.85B (+10.6%)
|
5.92B
est: 5.26B (+12.6%)
|
6.73B
est: 4.61B (+45.9%)
|
5.09B
est: 4.88B (+4.2%)
|
4.26B
est: 4.66B (-8.5%)
|
3.08B
est: 4.81B (-36.0%)
|
5.01B
5.01B – 5.01B
+4.1% YoY
|
5.35B
5.35B – 5.35B
+6.9% YoY
|
5.70B
5.70B – 5.70B
+6.4% YoY
|
| Net Income |
2.57B
est: 2.62B (-2.0%)
|
2.66B
est: 2.87B (-7.5%)
|
3.04B
est: 3.31B (-8.2%)
|
3.51B
est: 3.81B (-7.9%)
|
3.94B
est: 4.18B (-5.6%)
|
4.25B
est: 4.13B (+2.7%)
|
4.67B
est: 4.30B (+8.4%)
|
3.60B
est: 3.03B (+18.7%)
|
3.29B
est: 5.97B (-44.8%)
|
1.91B
est: 1.47B (+29.7%)
|
2.54B
2.54B – 2.54B
+72.6% YoY
|
2.69B
2.69B – 2.69B
+6.0% YoY
|
3.15B
3.15B – 3.15B
+17.0% YoY
|
| SGA |
2.35B
est: 2.88B (-18.4%)
|
2.39B
est: 3.12B (-23.2%)
|
2.30B
est: 3.08B (-25.3%)
|
2.39B
est: 3.18B (-24.7%)
|
2.61B
est: 3.48B (-25.0%)
|
2.71B
est: 3.77B (-28.1%)
|
2.99B
est: 3.31B (-9.6%)
|
3.08B
est: 3.50B (-12.1%)
|
3.43B
est: 3.79B (-9.4%)
|
3.33B
est: 3.92B (-14.9%)
|
4.08B
4.08B – 4.08B
+4.1% YoY
|
4.36B
4.36B – 4.36B
+6.9% YoY
|
4.64B
4.64B – 4.64B
+6.4% YoY
|
| EPS |
93.22
est: 86.09 (+8.3%)
|
96.48
est: 94.41 (+2.2%)
|
110.50
est: 108.95 (+1.4%)
|
127.61
est: 125.32 (+1.8%)
|
140.75
est: 137.36 (+2.5%)
|
141.38
est: 135.91 (+4.0%)
|
152.45
est: 141.50 (+7.7%)
|
113.82
est: 99.68 (+14.2%)
|
105.00
est: 202.85 (-48.2%)
|
62.72
est: 50.00 (+25.4%)
|
86.30
86.30 – 86.30
+72.6% YoY
|
91.50
91.50 – 91.50
+6.0% YoY
|
107.10
107.10 – 107.10
+17.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-28 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-27 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-26 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-25 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-01 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-1.62B
OE per share TTM
-52.73
Owner's Yield
-4.60%
Maintenance CapEx ratio
25.68%
Maint CapEx / Avg PPE
53.7%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 33 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Japan SmallCap Dividend Fund DFJ | 0.04% | 150.0K | 0.58% |
| 2 | Dimensional - International Small Cap Value ETF DISV | 0.03% | 1.27M | 0.42% |
| 3 | State Street SPDR S&P International Small Cap ETF GWX | 0.02% | 178.4K | 0.40% |
| 4 | Avantis International Small Cap Value ETF AVDV | 0.01% | 1.48M | 0.36% |
| 5 | Schwab International Small-Cap Equity ETF SCHC | 0.01% | 380.9K | 0.06% |
| 6 | Avantis International Small Cap Equity ETF AVDS | 0.01% | 21.8K | 0.30% |
| 7 | Dimensional - International Small Cap ETF DFIS | 0.01% | 355.4K | 0.39% |
| 8 | Avantis Global Small Cap Value UCITS ETF AVGS.L | 0.01% | 57.2K | 0.39% |
| 9 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 638.3K | 0.06% |
| 10 | Vanguard International Dividend Appreciation ETF VIGI | 0.00% | 378.0K | 0.07% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
3.40M
Shares Outstanding
29.16M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Eiichi Takata | Executive Officer & Head of Purchasing and Logistics Division | — | — |
| Hiroshi Matsumori | President, Chief Executive Officer & Representative Director | — | — |
| Kazushige Hizume | Senior Corp Officer, Head of Sales HQ, Head of Pharmaceutical Biz Div, GM of Tokyo Branch & Director | — | — |
| Kenji Otsuga | Executive Officer & Chief Financial Officer | — | — |
| Kiyoshi Takami | Managing Executive Officer & Shimo-okui Factory Manager | — | — |
| Masahiko Mouri | Executive Offi., Deputy Head of Production Divis. & GM of API Produ. Depart. and API Technical Offi. | — | — |
| Norio Kishi | Executive Officer, GM of Osaka Branch & Int. Business Dept. | — | — |
| Toru Ishida | Sen Corp Off, GM of Production Div., Formulation Manufacturing Dep & Env Safety Office and Director | — | — |
| Yoshinori Nakajima | Executive Off., Deputy Head of Production Division and GM of Production Planning & Management Dept. | — | — |
| Yutaka Kuwashima | Senior Corp Officer & Head of Quality and Regulatory Affairs Division | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4577.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
